Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs

Nov 17, 2010

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

Scientists in the USA have studied 20 that are targeted by existing therapies and found that there are significant changes to these genes in a broad range of patients' tumours, including many for which these drugs are not being used at present. The results suggest that these therapies, which have already been deemed safe and effective by regulatory agencies, may have additional opportunities to benefit patients.

However, Dr Daniel Rhodes, chief executive officer and co-founder of Scientific Applications at Compendia Bioscience (Ann Arbor, Michigan, USA), told the meeting: "While there may be immediate opportunities to use these new findings to treat patients with few remaining treatment options, broader application of the findings will require large-scale clinical trials to investigate if such personalised medicine could translate into real benefit over existing standard of care."

Genes can play a role in causing cancer in a number of ways, including via mutations that cause them to function incorrectly or via DNA amplifications whereby there are multiple additional copies of a gene. Normal cells (apart from ) typically have two copies of each gene, but often create additional copies of specific cancer-causing genes. For the current study, Dr Rhodes and his colleagues were looking for tumours in which there were five or more copies of a particular gene.

Targeted therapies are aimed at blocking the action of the mutated or amplified genes, "but they are often used without detailed knowledge of the of a patient's tumour," said Dr Rhodes. "The aim of personalised medicine is to understand an individual patient's cancer and select therapies that are most likely to benefit the patient; however, today most patients do not undergo any genetic testing of their tumours. We sought to understand the opportunity to use DNA amplifications, one type of cancer-causing mutation, to select existing targeted therapies that would be most likely to benefit cancer patients.

"We studied 22 genes that are targeted by therapies, either approved or in clinical trials, and found that the targets often show high-level amplifications in small subsets of patients and that particular cancer types show more frequent amplifications, for instance cancers of the brain (21.4% of cases) and breast (23.2% of cases). Our work suggests that some cancer patients should be tested for DNA amplifications and that small subsets of cancer patients harbour specific DNA amplifications that might indicate potential benefit from an existing therapy. We caution that we have not demonstrated that the targeted therapies will benefit all cancer patients with a DNA amplification, but we suspect, given past clinical trials and experimental studies, that some DNA amplifications will be predictive of therapeutic benefit for some patients."

The researchers studied the genes in tumours from 4,086 patients and found 592 significant DNA amplifications in 438 cancer patients, suggesting that 5-10% of cancer patients might be suitable for treatment with an existing targeted therapy. In addition to brain and breast cancers, they found significant amplifications in cancer of the colon (5.8%), lung (5.8%), ovary (4%) and pancreas (3%). They were rare or non-existent in liver cancer, leukaemia and myeloma. As might be expected, amplifications of the HER2 gene were found in breast cancer (13.7% frequency), at which the drug trastuzumab is targeted, but it was also found in small subsets of colorectal (1.3%) and lung (0.9%) cancer patients. There were examples of other gene amplifications occurring in cancers other than those for which targeted therapies had been tested and approved.

The researchers also checked whether the amplifications were ones that were responsible for driving the growth of the various cancers. "We cannot be sure that in each case the DNA amplifications we studied were 'drivers' of cancer, but we can look for clues that the genes are likely to be the drivers," explained Dr Rhodes. "If the amplifications involved small, focal regions of the genome that included only the target or only a few genes, then it is more likely that the target gene was a 'driver'. Also, if the target gene was more frequently amplified and amplified at higher levels than neighbour genes, then again it is more likely that the target gene is the 'driver'. Thus, we examined the regions of amplification around the target genes and the most commonly amplified genes in the region and in almost all cases, our target gene under study was the most commonly and most highly amplified gene in the region."

Dr Rhodes concluded: "We envision our work motivating a DNA amplification-guided clinical trial that would test advanced cancer patients for DNA amplification of all relevant targets and then partition patients into treatment arms based on their particular amplification. Such an effort would be costly and could require hundreds of patients; however, our study provides the basis and the frequencies of amplifications that could be expected. We hope that this work will motivate clinicians to consider such an approach."

Explore further: Preventing the spread of cancer with copper molecules

Provided by ECCO-the European CanCer Organisation

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Gene's cancer role is identified

Aug 08, 2006

U.S. medical researchers say they've discovered a new cancer-promoting role for a gene potentially linked with breast, liver and other kinds of cancer.

Gene's cancer role is identified

Aug 08, 2006

U.S. medical researchers say they've discovered a new cancer-promoting role for a gene potentially linked with breast, liver and other kinds of cancer.

Genes associated with aggressive breast cancer

Aug 16, 2010

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment ...

Recommended for you

US women's awareness of breast density varies

4 hours ago

Disparities in the level of awareness and knowledge of breast density exist among U.S. women, according to the results of a Mayo Clinic study published in the Journal of Clinical Oncology.

Study shows why some brain cancers resist treatment

4 hours ago

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.

Researchers identify genes responsible for lung tumors

6 hours ago

The lung transcription factor Nkx2-1 is an important gene regulating lung formation and normal respiratory functions after birth. Alterations in the expression of this transcription factor can lead to diseases such as lung ...

Lycopene may ward off kidney cancer in older women

8 hours ago

A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.